^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AlphaMedix (ORM-2110)

    i
    Other names: ORM-2110, 212 lead-labeled peptide, 212Pb AR RMX, 212-Pb-Targeted-Alpha-Emmitter-Therapy, 212Pb-AR-RMX, 212Pb-alphamedix, 212Pb-somatostatin analogue, Lead-212 radiotherapy, ORM 2110, ORM2110, 212Pb-labeled peptide, Pb212-octreotide analog, ²¹²Pb-DOTAMTATE, Pb-212 radiotherapy, SAR447873
    Company:
    Orano, RadioMedix, Sanofi
    Drug class:
    Alpha radiation emitter, SSTR2 modulator
    Related drugs:
    6ms
    ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
    P1, N=33, Terminated, Orano Med LLC | Recruiting --> Terminated; Terminated for non-safety reasons.
    Trial termination
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    6ms
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Orano Med LLC | Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    over1year
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Radiomedix, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    2years
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=68, Recruiting, Radiomedix, Inc. | N=34 --> 68 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Dec 2022 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    almost4years
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=34, Recruiting, Radiomedix, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    almost4years
    ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Radiomedix, Inc.
    Clinical • New P2 trial
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    over4years
    ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
    P1, N=33, Recruiting, Radiomedix, Inc. | Completed --> Recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    over4years
    ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
    P1, N=33, Completed, Radiomedix, Inc. | Recruiting --> Completed | N=50 --> 33 | Trial completion date: Nov 2021 --> Jul 2021
    Clinical • Trial completion • Enrollment change • Trial completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)
    over4years
    ALPHAMEDIX01: Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (clinicaltrials.gov)
    P1, N=50, Recruiting, Radiomedix, Inc. | Trial primary completion date: Jul 2020 --> Jun 2021
    Clinical • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (ORM-2110)